Last reviewed · How we verify
Rosuvastatin plus ticagrelor
At a glance
| Generic name | Rosuvastatin plus ticagrelor |
|---|---|
| Also known as | Crestor & Brilinta |
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions (NA)
- The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease
- The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) (PHASE4)
- Role of Immune Responses After Acute Myocardial Infarction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosuvastatin plus ticagrelor CI brief — competitive landscape report
- Rosuvastatin plus ticagrelor updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI